via Georgia Tech
Georgia Tech researchers have developed and tested an innovative method that may simplify the complexity of delivering Covid-19 and other vaccines through a handheld electroporator
Future vaccine delivery may rely on everyday items like BBQ lighters and microneedles, thanks to the ingenuity of a team of Georgia Institute of Technology and Emory University researchers.
The researchers, led by Georgia Tech’s School of Chemical and Biomolecular Engineering, have developed and tested an innovative method that may simplify the complexity of delivering Covid-19 and other vaccines through a handheld electroporator.
While electroporation is commonly employed in the research lab using short electric pulses to drive molecules into cells, the technique currently requires large, complex, and costly equipment, severely limiting its use for vaccine delivery. Georgia Tech’s approach does the job using a novel pen-size device that requires no batteries and can be mass produced at low cost.
The team’s findings are reported in the Oct. 20 issue of the Proceedings of the National Academy of Sciences.
The Aha Moment
The inspiration for their breakthrough came from an everyday device that people use to start a grill: the electronic barbecue lighter.
“My lab figured out that you could use something all of us are familiar with on the Fourth of July when we do a barbecue — a barbecue lighter,” recalled Saad Bhamla, assistant professor in the School of Chemical and Biomolecular Engineering, explaining that every time one clicks the lighter, it generates a brief pulse of electricity to ignite the flame.
His team took the innards of a lighter and reengineered them into a tiny spring-latch mechanism. The device creates the same electric field in the skin as the large bulky electroporation machines already in use, but using widely available, low-cost components that require no battery to operate.
“Our aha moment was the fact that it doesn’t have a battery or plug into the wall, unlike conventional electroporation equipment,” he explained. “And these lighter components cost just pennies, while currently available electroporators cost thousands of dollars each.”
Pairing the reimagined lighter device with microneedle technology from Georgia Tech’s Laboratory for Drug Delivery has resulted in a new ultra-low-cost electroporation system, or “ePatch.”
Closer Electrode Spacing, Lower Voltages
Besides the lighter, a key innovation involved tightly spacing the electrodes and using extremely short microneedles. While commonly used in cosmetics to rejuvenate skin and for potential medical applications, microneedles are not generally used as electrodes. Coupling the tiny electroporation pulser with microneedle electrodes made an effective electrical interface with the skin and further reduced the ePatch’s cost and complexity.
According to Mark Prausnitz, Regents’ Professor and the J. Erskine Love Jr. Chair in Chemical and Biomolecular Engineering, their microneedle-based system uses voltages similar to conventional electroporation but with pulses that are 10,000 times shorter and using electrodes that penetrate just .01 inch into the skin surface.
“The close spacing of the microneedles allows us to use microsecond pulses rather than the millisecond pulses applied in conventional electroporation. This shorter pulse, plus the shallow location of the microneedle electrodes, minimizes nerve and muscle stimulation, which can avoid pain and twitching, both common side effects of conventional electroporation,” he said.
“Our goal was to design a method for Covid-19 vaccination that uses a device that is simple, low-cost and manufacturable,” said Dengning Xia, lead author on the study while working as a research scientist at Georgia Tech and currently an associate professor at Sun Yat-sen University in China.
“The ePatch is a handheld device the size of a pen, weighing less than two ounces, and requiring no battery or power sources. It operates by simply pushing a button, which makes it very simple to use,” he said.
Testing for an Immune Response
But could their system be used with a vaccine to generate an immune response?
To find out, the researchers teamed with Chinglai Yang, associate professor in the Department of Microbiology and Immunology at Emory University School of Medicine, to test the delivery system first using a florescent protein to ensure it worked, and to deliver an actual Covid-19 vaccine. They selected an experimental DNA vaccine for Covid-19 as their model.
“In the beginning, I wasn’t sure that it would be successful when Georgia Tech asked me to collaborate on this project,” Yang said. “Surprisingly, even in the first try, it went far beyond my expectations. Using this method with the same amount of vaccine, the ePatch induced an almost tenfold improved immune response over intramuscular immunization or intradermal injection without electroporation. It also showed no lasting effects to the mice’s skin. What this means is that it is easier to achieve protection,” he said.
The researchers say the ePatch should also work for mRNA vaccination, which they are currently studying.
But devising a simpler, cost-effective electroporator that works with the DNA vaccine could dramatically reduce the cost and complexity of vaccinations since it doesn’t require deep-freeze storage of mRNA vaccines, which need frigid temperatures because they contain lipid nanoparticles.
“We think the key to making DNA vaccination work is to make electroporation simple, low-cost, and scalable,” Prausnitz said.
The ePatch is generating excitement among health experts, including Nadine Rouphael, professor of medicine and executive director of the Hope Clinic at the Emory Vaccine Center. She notes that today’s genetic vaccines, whether mRNA or DNA, remain expensive as a global solution because they either require a complicated cold chain and costly manufacturing due to the formulation of lipid nanoparticles for mRNA delivery or they need a sophisticated electroporation device for DNA vaccine delivery.
A Vaccine Delivery Breakthrough
“The Georgia Tech portable and affordable electroporation ePatch can overcome these limitations and can be a potential game changer in the vaccine delivery arena,” Rouphael predicted.
The researchers are already looking at ways to refine their system, examining how to optimize the immune response on the skin site and integrating the device into one unit.
“That would revolutionize the vaccination process,” Yang said.
The team must meet multiple milestones before human trials. Prausnitz anticipates it will be more than five years before their invention could complete clinical study and be ready for widespread use. He envisioned the ePatch following a more traditional device approval process than the accelerated vaccine approvals that happened during the pandemic.
All four researchers echo Rouphael’s enthusiasm for the potential of their ePatch to democratize access to vaccinations. Bhamla explained that vaccines work for those who can afford them and have access to healthcare resources, but that is not feasible for large segments of the developing world.
“We know that Covid-19 won’t be the last pandemic,” Bhamla said. “We need to think from a cost as well as design perspective about how to simplify and scale up our hardware so these modern interventions can be more equitably dispersed — to reach more underserved and more under-resourced areas of the world.”
The research team also included Gaurav Byagathvalli, Huan Yu, and Chao-Yi Lu from Georgia Tech and Rui Jin and Ling Ye from Emory University.
The Latest on: Vaccine delivery
- Strengthening research, development and vaccine manufacturing for pandemic preparedness in Africaon December 5, 2022 at 11:33 pm
In our globally connected world, where the risk of epidemics and pandemics is increasing, pandemic preparedness is crucial to protecting our future. The ...
- Nasal spray Covid-19 vaccine co-developed by Hong Kong scientists approved for emergency use in mainland China in ‘historic breakthrough’on December 5, 2022 at 8:03 am
Microbiologist Professor Yuen Kwok-yung and team created the emergency use nasal vaccine with mainland university and Beijing drug company Pharmaceutical firm confirms that vaccine has been given the ...
- New HIV Vaccine Trial Shows Extreme Promiseon December 4, 2022 at 7:43 am
A small, phase 1 trial testing a new HIV vaccine delivered positive results in 97 percent of recipients. The vaccine was created from an engineered version of a protein within the HIV virus. This ...
- An early-stage HIV vaccine is showing positive results. If it works, it would be first successful HIV vaccine after almost 40 years of research.on December 1, 2022 at 10:59 am
An early study found that recipients of an experimental HIV vaccine showed immune system activity. It could be a cause for hope in the long-running effort to find a vaccine.
- Novel Tablet-based Vaccine for Urinary Tract Infectionson November 30, 2022 at 5:34 pm
Urinary tract infections (UTIs) affect more than 50% of women Researchers developed a tablet-delivery vaccine for UTI that mobilizes essential immune cells to precisely combat bacteria that cause ...
- Urinary tract infections: Dissolving vaccine tablet as effective as antibioticson November 30, 2022 at 6:44 am
Researchers recently developed a sublingual vaccine tablet for urinary tract infections that dissolves under the tongue. The vaccine was as effective as high dose antibiotics in treating UTIs without ...
- Impact of an individually tailored educational application on vaccine attitudes of pregnant women and motherson November 29, 2022 at 11:01 am
Researchers evaluated the impact of MomsTalkShots, a personalized application, on maternal attitudes toward vaccinations.
- PharmaJet Receives NIH Grant to Evaluate use of Needle-free Intradermal Delivery for HPV Immunizationon November 29, 2022 at 8:14 am
This follows PharmaJet's preliminary studies evaluating intradermal delivery for HPV vaccines. 1 Intradermal administration is already widely used for polio vaccine delivery and has been found to be ...
- Tablet-based vaccine prevents urinary tract infections in miceon November 29, 2022 at 1:00 am
Biomedical engineers at Duke University have developed a tablet-based vaccine for urinary tract infections (UTIs) that rapidly dissolves when placed under the tongue. The new treatment could offer an ...
- Are nasal-spray vaccines the solution to respiratory infectious diseases?on November 27, 2022 at 10:05 pm
Nasal vaccine delivery systems Mucosal tissues have mechanisms to exclude foreign particles, which may prevent the efficient delivery of vaccine antigens. Therefore, a delivery vehicle that can ...
via Bing News
The Latest on: Vaccine delivery
[google_news title=”” keyword=”vaccine delivery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News